Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports

Andrea Michelerio, Mattia Novario, Stefania Barruscotti, Camilla Vassallo

Research output: Contribution to journalArticlepeer-review


It is known that individuals with immune dysregulation have an increased risk of non-Hodgkin lymphoma. This association has been proven for pemphigus as well as for other autoimmune disease. We describe the development of cutaneous B-cell lymphoma in two patients affected by long-standing pemphigus vulgaris and pemphigus foliaceus (i.e., characterized by histological and immunopathological features different from those of paraneoplastic pemphigus). In both cases, a therapy with rituximab allowed to achieve the complete remission for the lymphoproliferative disease (never recurred at follow up) and a substantial long-term improvement of the clinical manifestations of pemphigus, although persistent to serological disease and occasional recurrences. We suggest that clinicians should consider that patients with long-standing pemphigus, both vulgaris and foliaceus, may develop primary cutaneous B-cell lymphomas, as shown in our report, and in these cases the treatment with rituximab is elective, providing a therapeutic option for both low-grade or follicular, CD20-positive, B-cell non-Hodgkin lymphomas and pemphigus. Nevertheless, as shown in our cases, a constant surveillance for pemphigus is necessary.

Original languageEnglish
Article numbere12948
JournalDermatologic Therapy
Publication statusPublished - Jan 1 2019


  • autoimmune disease
  • lymphoma
  • pemphigus
  • rituximab

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports'. Together they form a unique fingerprint.

Cite this